Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells.

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. Abstract Text:

Brian P Dolan,Kenneth D Gibbs,Suzanne Ostrand-Rosenberg,

The activation of naive CD8+ T cells has been attributed to two mechanisms: cross-priming and direct priming. Cross-priming and direct priming differ in the source of Ag and in the cell that presents the Ag to the responding CD8+ T cells. In cross-priming, exogenous Ag is acquired by professional APCs, such as dendritic cells (DC), which process the Ag into peptides that are subsequently presented. In direct priming, the APCs, which may or may not be DC, synthesize and process the Ag and present it themselves to CD8+ T cells. In this study, we demonstrate that naive CD8+ T cells are activated by a third mechanism, called cross-dressing. In cross-dressing, DC directly acquire MHC class I-peptide complexes from dead, but not live, donor cells by a cell contact-mediated mechanism, and present the intact complexes to naive CD8+ T cells. Such DC are cross-dressed because they are wearing peptide-MHC complexes generated by other cells. CD8+ T cells activated by cross-dressing are restricted to the MHC class I genotype of the donor cells and are specific for peptides generated by the donor cells. In vivo studies demonstrate that optimal priming of CD8+ T cells requires both cross-priming and cross-dressing. Thus, cross-dressing may be an important mechanism by which DC prime naive CD8+ T cells and may explain how CD8+ T cells are primed to Ags that are inefficiently cross-presented.

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. Publishing Authors By Initials

BP Dolan,KD Gibbs,S Ostrand-Rosenberg,

For similar peptides research abstracts see: peptides research

PUBMED ID PMID:

MEDLINE DATE:

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of immunology (Baltimore, Md. : 1950)

VOLUME: 177

Page Numbers: 6018-24

Journal Abbreviation: J. Immunol.

ISSN: 0022-1767

DAY: 1

MONTH: Nov

YEAR: 2006

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985117

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. Keywords Mesh Terms:

KEYWORDS: Peptides

MESH TERMS: immunology

Chemical & Substance for Abstract: Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. Information

Substance Name: Peptides

Registry Number: 0

Grant and Affiliation Information for Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells.

AFFILIATION: Department of Biological Sciences, University of Maryland-Baltimore County, Baltimore, MD 21250, USA.

Country: United States

AGENCY: United States NIGMS

GRANT: GM 08663

ACRONYM: GM

MEDLINETA: J Immunol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells Related Publications

• Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.
• Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells.
• Immune surveillance: a balance between protumor and antitumor immunity.
• Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.
• MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
• Mouse 4T1 breast tumor model.
• Mouse SaI sarcoma tumor model.
• Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
• Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.
• The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4(+) T lymphocytes.